---
reference_id: "PMID:27455347"
title: NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.
authors:
- Kenna KP
- van Doormaal PT
- Dekker AM
- Ticozzi N
- Kenna BJ
- Diekstra FP
- van Rheenen W
- van Eijk KR
- Jones AR
- Keagle P
- Shatunov A
- Sproviero W
- Smith BN
- van Es MA
- Topp SD
- Kenna A
- Miller JW
- Fallini C
- Tiloca C
- McLaughlin RL
- Vance C
- Troakes C
- Colombrita C
- Mora G
- Calvo A
- Verde F
- Al-Sarraj S
- King A
- Calini D
- de Belleroche J
- Baas F
- van der Kooi AJ
- de Visser M
- Ten Asbroek AL
- Sapp PC
- McKenna-Yasek D
- Polak M
- Asress S
- Muñoz-Blanco JL
- Strom TM
- Meitinger T
- Morrison KE
- SLAGEN Consortium
- Lauria G
- Williams KL
- Leigh PN
- Nicholson GA
- Blair IP
- Leblond CS
- Dion PA
- Rouleau GA
- Pall H
- Shaw PJ
- Turner MR
- Talbot K
- Taroni F
- Boylan KB
- Van Blitterswijk M
- Rademakers R
- Esteban-Pérez J
- García-Redondo A
- Van Damme P
- Robberecht W
- Chio A
- Gellera C
- Drepper C
- Sendtner M
- Ratti A
- Glass JD
- Mora JS
- Basak NA
- Hardiman O
- Ludolph AC
- Andersen PM
- Weishaupt JH
- Brown RH Jr
- Al-Chalabi A
- Silani V
- Shaw CE
- van den Berg LH
- Veldink JH
- Landers JE
journal: Nat Genet
year: '2016'
doi: 10.1038/ng.3626
content_type: abstract_only
---

# NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.
**Authors:** Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, van Rheenen W, van Eijk KR, Jones AR, Keagle P, Shatunov A, Sproviero W, Smith BN, van Es MA, Topp SD, Kenna A, Miller JW, Fallini C, Tiloca C, McLaughlin RL, Vance C, Troakes C, Colombrita C, Mora G, Calvo A, Verde F, Al-Sarraj S, King A, Calini D, de Belleroche J, Baas F, van der Kooi AJ, de Visser M, Ten Asbroek AL, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Muñoz-Blanco JL, Strom TM, Meitinger T, Morrison KE, SLAGEN Consortium, Lauria G, Williams KL, Leigh PN, Nicholson GA, Blair IP, Leblond CS, Dion PA, Rouleau GA, Pall H, Shaw PJ, Turner MR, Talbot K, Taroni F, Boylan KB, Van Blitterswijk M, Rademakers R, Esteban-Pérez J, García-Redondo A, Van Damme P, Robberecht W, Chio A, Gellera C, Drepper C, Sendtner M, Ratti A, Glass JD, Mora JS, Basak NA, Hardiman O, Ludolph AC, Andersen PM, Weishaupt JH, Brown RH Jr, Al-Chalabi A, Silani V, Shaw CE, van den Berg LH, Veldink JH, Landers JE
**Journal:** Nat Genet (2016)
**DOI:** [10.1038/ng.3626](https://doi.org/10.1038/ng.3626)

## Content

1. Nat Genet. 2016 Sep;48(9):1037-42. doi: 10.1038/ng.3626. Epub 2016 Jul 25.

NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.

Kenna KP(1), van Doormaal PT(2), Dekker AM(2), Ticozzi N(3)(4), Kenna BJ(1), 
Diekstra FP(2), van Rheenen W(2), van Eijk KR(2), Jones AR(5), Keagle P(1), 
Shatunov A(5), Sproviero W(5), Smith BN(5), van Es MA(2), Topp SD(5), Kenna 
A(1), Miller JW(5), Fallini C(1), Tiloca C(3)(6), McLaughlin RL(7), Vance C(5), 
Troakes C(5), Colombrita C(3)(4), Mora G(8), Calvo A(9), Verde F(3)(4), 
Al-Sarraj S(5), King A(5), Calini D(3), de Belleroche J(10), Baas F(11), van der 
Kooi AJ(12), de Visser M(12), Ten Asbroek AL(11), Sapp PC(1), McKenna-Yasek 
D(1), Polak M(13), Asress S(13), Muñoz-Blanco JL(14), Strom TM(15), Meitinger 
T(16), Morrison KE(17); SLAGEN Consortium; Lauria G(18), Williams KL(19), Leigh 
PN(20), Nicholson GA(19)(21), Blair IP(19), Leblond CS(22), Dion PA(22), Rouleau 
GA(22), Pall H(23)(24), Shaw PJ(25), Turner MR(25), Talbot K(25), Taroni F(26), 
Boylan KB(27), Van Blitterswijk M(28), Rademakers R(28), Esteban-Pérez 
J(29)(30), García-Redondo A(29)(30), Van Damme P(31)(32), Robberecht W(31)(32), 
Chio A(9), Gellera C(26), Drepper C(33)(34), Sendtner M(33), Ratti A(3)(4), 
Glass JD(13), Mora JS(35), Basak NA(36), Hardiman O(7), Ludolph AC(37), Andersen 
PM(38), Weishaupt JH(37), Brown RH Jr(1), Al-Chalabi A(5), Silani V(3)(4), Shaw 
CE(5), van den Berg LH(2), Veldink JH(2), Landers JE(1).

Collaborators: D'Alfonso S, Mazzini L, Comi GP, Del Bo R, Ceroni M, Gagliardi S, 
Querin G, Bertolin C, Pensato V, Castellotti B, Corti S, Cereda C, Corrado L, 
Sorarù G.

Author information:
(1)Department of Neurology, University of Massachusetts Medical School, 
Worcester, Massachusetts, USA.
(2)Department of Neurology Brain Centre, Brain Centre Rudolf Magnus, University 
Medical Centre Utrecht, Utrecht, the Netherlands.
(3)Department of Neurology, IRCCS Istituto Auxologico Italiano, Milan, Italy.
(4)Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, 
Università degli Studi di Milano, Milan, Italy.
(5)Maurice Wohl Clinical Neuroscience Institute, King's College London, 
Department of Basic and Clinical Neuroscience, Institute of Psychiatry, 
Psychology and Neuroscience, London, UK.
(6)Doctoral School in Molecular Medicine, Department of Sciences and Biomedical 
Technologies, Università degli Studi di Milano, Milan, Italy.
(7)Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity 
College Dublin, Dublin, Ireland.
(8)Salvatore Maugeri Foundation, IRCSS, Scientific Institute of Milano, Milan, 
Italy.
(9)'Rita Levi Montalcini' Department of Neuroscience, ALS Centre, University of 
Torino, Turin, Italy.
(10)Neurogenetics Group, Division of Brain Sciences, Imperial College London, 
London, UK.
(11)Department of Clinical Genetics, Academic Medical Centre, University of 
Amsterdam, Amsterdam, the Netherlands.
(12)Department of Neurogenetics and Neurology, Academic Medical Centre, 
University of Amsterdam, Amsterdam, the Netherlands.
(13)Department of Neurology, Emory University, Atlanta, Georgia, USA.
(14)Unidad de ELA, Instituto de Investigación Hospital Gregorio Marañón de 
Madrid, Madrid, Spain.
(15)Institute of Human Genetics, Helmholtz Zentrum München-German Research 
Center for Environmental Health, Neuherberg, Germany.
(16)Institute of Human Genetics, Technische Universität München, Munich, 
Germany.
(17)Faculty of Medicine, University of Southampton, Southampton, UK.
(18)3rd Neurology Unit, Motor Neuron Diseases Center, Fondazione IRCCS Istituto 
Neurologico 'Carlo Besta', Milan, Italy.
(19)Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New 
South Wales, Australia.
(20)Trafford Centre for Medical Research, Brighton and Sussex Medical School, 
Falmer, UK.
(21)ANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, 
New South Wales, Australia.
(22)Montreal Neurological Institute, Department of Neurology and Neurosurgery, 
McGill University, Montreal, Quebec, Canada.
(23)Institute of Clinical Studies, College of Medical and Dental Sciences, 
University of Birmingham, Edgbaston, Birmingham, UK.
(24)Department of Neurology, Queen Elizabeth Hospital Birmingham, Edgbaston, 
Birmingham, UK.
(25)Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, 
UK.
(26)Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione 
IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy.
(27)Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
(28)Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
(29)Unidad de ELA, Instituto de Investigación Hospital 12 de Octubre de Madrid, 
Madrid, Spain.
(30)Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) 
U-723, Madrid, Spain.
(31)Laboratory of Neurobiology, Department of Neurosciences, KU Leuven and 
Vesalius Research Centre, VIB, Leuven, Belgium.
(32)Department of Neurology, University Hospitals, Leuven, Belgium.
(33)Institute of Clinical Neurobiology, University Hospital Würzburg, Würzburg, 
Germany.
(34)Department of Child and Adolescent Psychiatry, University Hospital of 
Würzburg, Würzburg, Germany.
(35)ALS Unit/Neurology, Hospital San Rafael, Madrid, Spain.
(36)NDAL, Department of Molecular Biology and Genetics, Bogazici University, 
Istanbul, Turkey.
(37)Neurology Department, Ulm University, Ulm, Germany.
(38)Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, 
Sweden.

To identify genetic factors contributing to amyotrophic lateral sclerosis (ALS), 
we conducted whole-exome analyses of 1,022 index familial ALS (FALS) cases and 
7,315 controls. In a new screening strategy, we performed gene-burden analyses 
trained with established ALS genes and identified a significant association 
between loss-of-function (LOF) NEK1 variants and FALS risk. Independently, 
autozygosity mapping for an isolated community in the Netherlands identified a 
NEK1 p.Arg261His variant as a candidate risk factor. Replication analyses of 
sporadic ALS (SALS) cases and independent control cohorts confirmed significant 
disease association for both p.Arg261His (10,589 samples analyzed) and NEK1 LOF 
variants (3,362 samples analyzed). In total, we observed NEK1 risk variants in 
nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, 
including cilia formation, DNA-damage response, microtubule stability, neuronal 
morphology and axonal polarity. Our results provide new and important insights 
into ALS etiopathogenesis and genetic etiology.

DOI: 10.1038/ng.3626
PMCID: PMC5560030
PMID: 27455347 [Indexed for MEDLINE]

Conflict of interest statement: COMPETING FINANCIAL INTERESTS The authors 
declare no competing financial interests.